⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALGS News
Aligos Therapeutics, Inc. Common Stock
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
globenewswire.com
ALGS
Form 8-K
sec.gov
ALGS
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
globenewswire.com
ALGS
Algenesis Cuts Carbon Footprint by Up to 65% with Soleic® Bio-Based Materials
prnewswire.com
ALGS
ECU Worldwide presenta l'espansione di XLERATE 2.0 per evitare le interruzioni nella catena di fornitura tra Europa e Asia
businesswire.com
ALGS
Unanet and Algorithms Software Expand Partnership to North America, Giving Construction Companies End-to End Capabilities From Opportunity to Delivery
prnewswire.com
ALGS
NAYA Therapeutics Announces World-Class Board of Directors
accessnewswire.com
AMGN
NVAX
MRK
CDXS
ABBV
ALGS
Form 8-K
sec.gov
ALGS
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
ALGS
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
globenewswire.com
ALGS